Results 181 to 190 of about 74,972 (273)

RNA Modifications in Tumor Microenvironment: A New Dimension for Cancer Treatment

MedComm, Volume 7, Issue 7, July 2026.
Tumor initiation and progression depend on a supportive and highly heterogeneous tumor microenvironment (TME). RNA modifications regulate signaling pathways and cytokine networks that shape TME dynamics, facilitating interactions between cancer cells and noncancerous stromal cells, and ultimately promoting immune evasion and tumor progression ...
Qiwen Li, Yating Sun, Shuibin Lin, Quan Yuan   +3 more
wiley   +1 more source

Chemical and Technological Aspects of Magnetic Particles for Cancer Liquid Biopsy Applications

ChemistryOpen, Volume 15, Issue 7, July 2026.
Magnetic bead engineering for liquid biopsy diagnostics reviews advances in magnetic bead design for the selective enrichment of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) from complex biofluids.
Beatriz Naranjo‐Martínez, Ana Laura Coria‐Gutiérrez, Sunčica Sukur, Sedef Ozel‐Okcu, Václav Ranc, Francisco J. Terán, Franca Raucci, Marco A. Pierotti, Domenico Scionti, Anna Piperno   +9 more
wiley   +1 more source

Molecular Interplay of PARN and Telomerase: Tail Modifiers and Disease Implications

WIREs RNA, Volume 17, Issue 4, July/August 2026.
Schematic representation of the molecular interplay between PARN, telomerase‐associated, and the involvement of p53 in regulating telomere maintenance and genome stability. The top panel shows how normal PARN levels are involved in regulating p53 levels and balanced telomerase activity through their regulatory interaction with TERC and TERRA, thus ...
Sujitha Felicitus, Shalon Suzanne Pinto, Sai Samanvitha Madagundapalli Ramakrishna, Dechamma Pandyanada Nanjappa, Gunimala Chakraborty, Anirban Chakraborty   +5 more
wiley   +1 more source

BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma

Thoracic Cancer, Volume 17, Issue 13, July 2026.
We evaluated whether BAP1 loss is associated with clinical outcomes following immunotherapy. BAP1 loss shows better progression‐free survival (PFS), but we can't conclude that BAP1 loss is a favorable predictive biomarker. The reason is that BAP1 loss may have a better baseline prognosis, and it is necessary to consider the interactions with other ...
Reina Imase, Rie Sakakibara, Susumu Kirimura, Hironori Ishibashi, Kenichi Okubo, Yasunari Miyazaki   +5 more
wiley   +1 more source

Engineering Extracellular Vesicles for Anti‐Aging Therapy: Mechanisms, Applications, and Perspectives

Aging Cell, Volume 25, Issue 7, July 2026.
This review systematically elucidates the multifactorial anti‐aging mechanisms of extracellular vesicles (EVs). By bridging fundamental biology with advanced bioengineering, scalable manufacturing, and clinical translation, it establishes a comprehensive framework for developing next‐generation EVs‐based precision nanotherapeutics to combat systemic ...
Xian Huang, Qiujie Li, Guofang Tao, Xulin Gan, Jiangjie Lu, Sergei Krasny, Liyun Shi   +6 more
wiley   +1 more source

Malignant craniopharyngiomas: Institutional experience and literature review

Brain Pathology, Volume 36, Issue 4, July 2026.
We report the second case of malignant craniopharyngioma with BAP1 and TP53 mutations. A literature review identified 44 cases of malignant craniopharyngiomas with a median overall survival of 6 months. Eighteen (41%) occurred in patients without any history of radiation, suggesting that mechanisms other than radiation have contributed to their ...
Thomas J. Auen, Isabella W. Zhang, Weiwei Zhang, Jordan M. Burr, Matthew L. Carda, James L. Wisecarver, Nicole Shonka, Jesse L. Cox, Sahara J. Cathcart, Allison Cushman‐Vokoun, Jie Chen   +10 more
wiley   +1 more source

TONSL Promotes Hepatocellular Carcinoma Progression by Inhibiting Apoptosis Through Homologous Recombination Repair

Cancer Science, Volume 117, Issue 7, Page 1852-1866, July 2026.
In hepatocellular carcinoma, the 8q24.3 locus is frequently amplified and is associated with tumor‐specific overexpression of TONSL. TONSL promotes homologous recombination repair through RAD51, limits γH2AX accumulation and apoptosis, supports tumor growth, and its loss increases sensitivity to poly (ADP‐ribose) polymerase (PARP) inhibition.
Akinori Tsujimoto, Hajime Otsu, Takashi Ofuchi, Tomohiko Ikehara, Kosuke Hirose, Shohei Shibuta, Kazuki Omachi, Yu Takahashi, Yuya Ono, Satoshi Higuchi, Takanari Tatsumi, Kiyotaka Hosoda, Qingjiang Hu, Yusuke Yonemura, Takaaki Masuda, Masayuki Sho, Koshi Mimori   +16 more
wiley   +1 more source

BRCA1 deficiency induces NFκB-dependent type-I interferon signaling in fallopian tube epithelial cells. [PDF]

Neoplasia
Madaan V, Kollara A, Spaner D, Brown TJ.
europepmc   +1 more source

Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study

Cancer Science, Volume 117, Issue 7, Page 1985-1995, July 2026.
In patients with mCSPC treated with apalutamide plus ADT, baseline ctDNA predicted earlier progression to CRPC and worse overall survival. Exploratory genome‐wide analysis identified 12 SNPs associated with apalutamide‐related skin rash. ABSTRACT Despite promising evidence of the efficacy of the androgen deprivation therapy (ADT) plus apalutamide in ...
Masaki Shiota, Taku Naiki, Koji Hatano, Akira Yokomizo, Hiroaki Tsuchiya, Yoko Takahashi, Taku Nakayama, Masaki Yoshida, Hirotsugu Uemura   +8 more
wiley   +1 more source

Domain-Specific Computational, Functional and Structural Methods Enable Interpretation of <i>BRCA1</i> BRCT Variants of Uncertain Significance. [PDF]

Curr Oncol
Torretto GC, Martin MD, Islam K, Archer NE, Feilotter HE, Davey SK.   +5 more
europepmc   +1 more source